HDAC Inhibition by SNDX-275 (Entinostat) Restores Expression of Silenced Leukemia-associated Transcription Factors Nur77 and Nor1 and of Key Pro-apoptotic Proteins in AML

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2012 Dec 19

PMID 23247046

Citations 33

Authors

L Zhou

V R Ruvolo

T McQueen

W Chen

I J Samudio

O Conneely

M Konopleva

M Andreeff

Affiliations

Soon will be listed here.

Abstract

Nur77 and Nor1 are highly conserved orphan nuclear receptors. We have recently reported that nur77(-/-)nor1(-/-) mice rapidly develop acute myeloid leukemia (AML) and that Nur77 and Nor1 transcripts were universally downregulated in human AML blasts. These findings indicate that Nur77 and Nor1 function as leukemia suppressors. We further demonstrated silencing of Nur77 and Nor1 in leukemia stem cells (LSCs). We here report that inhibition of histone deacetylase (HDAC) using the specific class I HDAC inhibitor SNDX-275 restored the expression of Nur77/Nor1 and induced expression of activator protein 1 transcription factors c-Jun and JunB, and of death receptor TRAIL, in AML cells and in CD34(+)/38(-) AML LSCs. Importantly, SNDX-275 induced extensive apoptosis in AML cells, which could be suppressed by silencing nur77 and nor1. In addition, pro-apoptotic proteins Bim and Noxa were transcriptionally upregulated by SNDX-275 in AML cells and in LSCs. Our present work is the first report of a novel mechanism of HDAC inhibitor-induced apoptosis in AML that involves restoration of the silenced nuclear receptors Nur77 and Nor1, activation of activator protein 1 transcription factors, a death receptor and pro-apoptotic proteins.

Citing Articles

Controversy and multiple roles of the solitary nucleus receptor Nur77 in disease and physiology.

Wang Y, Li N, Guan W, Wang D FASEB J. 2025; 39(6):e70468.

PMID: 40079203 PMC: 11904867. DOI: 10.1096/fj.202402775RR.

Histone deacetylase inhibitors for leukemia treatment: current status and future directions.

Hosseini M, Sanaat Z, Akbarzadeh M, Vaez-Gharamaleki Y, Akbarzadeh M Eur J Med Res. 2024; 29(1):514.

PMID: 39456044 PMC: 11515273. DOI: 10.1186/s40001-024-02108-8.

Targeting histone demethylases JMJD3 and UTX: selenium as a potential therapeutic agent for cervical cancer.

Chen D, Cai B, Zhu Y, Ma Y, Yu X, Xiong J Clin Epigenetics. 2024; 16(1):51.

PMID: 38576048 PMC: 10993516. DOI: 10.1186/s13148-024-01665-3.

Exploring the nexus of nuclear receptors in hematological malignancies.

Manickasamy M, Sajeev A, BharathwajChetty B, AlQahtani M, Abbas M, Hegde M Cell Mol Life Sci. 2024; 81(1):78.

PMID: 38334807 PMC: 10858172. DOI: 10.1007/s00018-023-05085-z.

Z-ligustilide preferentially caused mitochondrial dysfunction in AML HL-60 cells by activating nuclear receptors NUR77 and NOR1.

Liu G, Chen Z, Yang L, Rong Y, Wang Q, Li L Chin Med. 2023; 18(1):123.

PMID: 37735686 PMC: 10512564. DOI: 10.1186/s13020-023-00808-7.

References

Rowley J, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S . All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood. 1997; 90(2):535-41. View

Gajjar M, Candeias M, Malbert-Colas L, Mazars A, Fujita J, Olivares-Illana V . The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell. 2012; 21(1):25-35. DOI: 10.1016/j.ccr.2011.11.016. View

Giles R, Peters D, Breuning M . Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. 1998; 14(5):178-83. DOI: 10.1016/s0168-9525(98)01438-3. View

Stone R, ODonnell M, Sekeres M . Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004; :98-117. DOI: 10.1182/asheducation-2004.1.98. View

Colley S, Leedman P . Steroid Receptor RNA Activator - A nuclear receptor coregulator with multiple partners: Insights and challenges. Biochimie. 2011; 93(11):1966-72. DOI: 10.1016/j.biochi.2011.07.004. View

Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo P, Kitada S . Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006; 10(5):375-88. DOI: 10.1016/j.ccr.2006.10.006. View

Thompson J, Winoto A . During negative selection, Nur77 family proteins translocate to mitochondria where they associate with Bcl-2 and expose its proapoptotic BH3 domain. J Exp Med. 2008; 205(5):1029-36. PMC: 2373836. DOI: 10.1084/jem.20080101. View

Kolluri S, Bruey-Sedano N, Cao X, Lin B, Lin F, Han Y . Mitogenic effect of orphan receptor TR3 and its regulation by MEKK1 in lung cancer cells. Mol Cell Biol. 2003; 23(23):8651-67. PMC: 262666. DOI: 10.1128/MCB.23.23.8651-8667.2003. View

Pei L, Castrillo A, Chen M, Hoffmann A, Tontonoz P . Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli. J Biol Chem. 2005; 280(32):29256-62. DOI: 10.1074/jbc.M502606200. View

10.

Kang S, Na H, Kang H, Kim S, Lee M, Lee M . Regulation of Nur77 protein turnover through acetylation and deacetylation induced by p300 and HDAC1. Biochem Pharmacol. 2010; 80(6):867-73. DOI: 10.1016/j.bcp.2010.04.026. View

11.

Ulveling D, Francastel C, Hube F . When one is better than two: RNA with dual functions. Biochimie. 2010; 93(4):633-44. DOI: 10.1016/j.biochi.2010.11.004. View

12.

Wang J, Saunthararajah Y, Redner R, Liu J . Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res. 1999; 59(12):2766-9. View

13.

Wang J, Hoshino T, Redner R, Kajigaya S, Liu J . ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A. 1998; 95(18):10860-5. PMC: 27986. DOI: 10.1073/pnas.95.18.10860. View

14.

Williams G, Lau L . Activation of the inducible orphan receptor gene nur77 by serum growth factors: dissociation of immediate-early and delayed-early responses. Mol Cell Biol. 1993; 13(10):6124-36. PMC: 364672. DOI: 10.1128/mcb.13.10.6124-6136.1993. View

15.

Youn H, Sun L, Prywes R, Liu J . Apoptosis of T cells mediated by Ca2+-induced release of the transcription factor MEF2. Science. 1999; 286(5440):790-3. DOI: 10.1126/science.286.5440.790. View

16.

Lee S, Wesselschmidt R, Linette G, Kanagawa O, Russell J, Milbrandt J . Unimpaired thymic and peripheral T cell death in mice lacking the nuclear receptor NGFI-B (Nur77). Science. 1995; 269(5223):532-5. DOI: 10.1126/science.7624775. View

17.

Fraga M, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G . Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005; 37(4):391-400. DOI: 10.1038/ng1531. View

18.

Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda W . Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2007; 111(3):1060-6. DOI: 10.1182/blood-2007-06-098061. View

19.

Sibayama-Imazu T, Fujisawa Y, Masuda Y, Aiuchi T, Nakajo S, Itabe H . Induction of apoptosis in PA-1 ovarian cancer cells by vitamin K2 is associated with an increase in the level of TR3/Nur77 and its accumulation in mitochondria and nuclei. J Cancer Res Clin Oncol. 2008; 134(7):803-12. DOI: 10.1007/s00432-007-0349-z. View

20.

Bolden J, Peart M, Johnstone R . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5(9):769-84. DOI: 10.1038/nrd2133. View